Bobkova V I, Kartitskií V S, Lapkes T G, Mazurova S V
Kardiologiia. 1975 May;15(5):105-8.
Aldactone-saltucine was used in 52 patients with Stage IIB-III cardiac failure. The efficiency of the drug was evaluated by the dynamics of the clinical course, diuresis, body weight, blood and urine levels of electrolytes, and in some patients by the urine excretion of aldosterone. Aldactone-saltucine is a sufficiently effective diuretic agent that, without producing excessively fast diuresis, exerts after a course of therapy a beneficial effect, increasing mainly natriuresis, without concomitant hypokalemia. The diuretic effect of the drug ensued irrespectful of the initial level of urine aldosterone excretion. After a course of treatment urine aldosterone excretion tended to increase. Hyperaldosteronuria was noted in only 1/3 of the patients.
安体舒通 - 索图辛用于52例IIB - III期心力衰竭患者。通过临床病程动态、利尿、体重、血液和尿液电解质水平评估药物疗效,部分患者还通过醛固酮尿排泄量进行评估。安体舒通 - 索图辛是一种足够有效的利尿剂,不会产生过快的利尿作用,在一个疗程治疗后发挥有益作用,主要增加钠排泄,且不会伴有低钾血症。该药物的利尿作用与尿液醛固酮排泄的初始水平无关。经过一个疗程的治疗后,尿液醛固酮排泄量趋于增加。仅1/3的患者出现醛固酮增多症。